PATENT
ATTORNEY DOCKET NO. 50458/002001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Christian Korherr	Confirmation No.:	7111
Serial No.:	10/574,306	Art Unit:	1614
§ 371 date:	August 7, 2006	Examiner:	Not yet assigned
Customer No.:	21559		
Title:	MEDICAL USE OF TBK-1 OR OF INHIBITORS THEREOF		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

In reply to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, Applicants submit that the requirements had been met on August 7, 2006 with the submission of a Biochemical Sequence Diskette, along with a Substitute Sequence Listing and a Substitute Statement under 37 C.F.R. § 1.821(a).

Enclosed in support of the present reply are copies of the following:

■ a copy of the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed October 2, 2006;

■ a copy of the Substitute Sequence Listing and the Substitute Statement under 37 C.F.R. § 1.821(a) including a certificate of mailing under 37 C.F.R. § 1.10 dated August 7, 2006, as printed from the Patent Application Information Retrieval Image File Wrapper;

■ a copy of the Notice of Acceptance of Application, mailed March 23, 2007, indicating the receipt of a Biochemical Sequence Diskette on August 7, 2006; and

■ a copy of a Notice produced by the Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) indicating that the raw sequence listing had been entered without detected error on March 13, 2007, as printed from the Patent Application Information Retrieval Image File Wrapper.

Because Applicants had complied with the requirements for patent applications containing nucleotide and/or amino acid sequence disclosures prior to the mailing of the included notice, Applicants believe that there are no fees due at this time. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: April 30, 2007

Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

MAY 0 2 2007

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/574,306	Christian Korherr	50458002001

21559
CLARK & ELBING LLP
101 FEDERAL STREET
BOSTON, MA 02110

ACTION DUE Seq. List
DUE DATE 12.2.06
ESP 5.2.07
INITIALS TM

INTERNATIONAL APPLICATION NO.		
PCT/EP04/10996		
I.A. FILING DATE	PRIORITY DATE	
10/01/2004	10/02/2003	

CONFIRMATION NO. 7111

371 FORMALITIES LETTER

OC000000020642166

Date Mailed: 10/02/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

DEBORAH D WILLIAMS

CIPE

Telephone: (703) 308-9140 EXT 205

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/574,306	PCT/EP04/10996	50458002001

FORM PCT/DO/EO/922 (371 Formalities Notice)

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/574,306	Christian Korherr	50458/002001

INTERNATIONAL APPLICATION NO.	
PCT/EP04/10996	
I.A. FILING DATE	PRIORITY DATE
10/01/2004	10/02/2003

21559
CLARK & ELBING LLP
101 FEDERAL STREET
BOSTON, MA 02110

CONFIRMATION NO. 7111

371 ACCEPTANCE LETTER

OC000000023032427

Date Mailed: 03/23/2007

NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.495

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

08/07/2006
DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS

08/07/2006
DATE OF COMPLETION OF ALL 35 U.S.C. 371 REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. THE DATE APPEARING ON THE FILING RECEIPT AS THE " FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 (c)(1), (c)(2) and (c)(4) REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE. *The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.*

The following items have been received:

- Copy of the International Application filed on 04/03/2006
- Copy of the International Search Report filed on 04/03/2006
- Copy of IPE Report filed on 08/07/2006
- Preliminary Amendments filed on 04/03/2006
- Information Disclosure Statements filed on 08/07/2006
- Biochemical Sequence Diskette filed on 08/07/2006
- Oath or Declaration filed on 08/07/2006
- Biochemical Sequence Listing filed on 04/03/2006
- Request for Immediate Examination filed on 04/03/2006
- U.S. Basic National Fees filed on 04/03/2006
- Priority Documents filed on 04/03/2006

- Power of Attorney filed on 08/07/2006
- Specification filed on 04/03/2006
- Claims filed on 04/03/2006
- Abstracts filed on 04/03/2006
- Drawings filed on 04/03/2006

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

DEBORAH D WILLIAMS
Telephone: (703) 308-9140 EXT 205

PART 3 - OFFICE COPY

FORM PCT/DO/EO/903 (371 Acceptance Notice)

RAW SEQUENCE LISTING

The Biotechnology Systems Branch of the Scientific and Technical
Information Center (STIC) no errors detected.

Application Serial Number: _____10/574,306_____

Source: _____IFWP_____

Date Processed by STIC: _____03/13/2007_____

ENTERED

IFWP

```
 3 <110> APPLICANT: Korherr, Christian
 5 <120> TITLE OF INVENTION: Medical Use of TBK-1 or of Inhibitors Thereof
 7 <130> FILE REFERENCE: 50458/002001
 9 <140> CURRENT APPLICATION NUMBER: US 10/574,306
10 <141> CURRENT FILING DATE: 2006-04-03
12 <150> PRIOR APPLICATION NUMBER: PCT/EP2004/010996
13 <151> PRIOR FILING DATE: 2004-10-01
15 <150> PRIOR APPLICATION NUMBER: US 60/508,100
16 <151> PRIOR FILING DATE: 2003-10-02
18 <160> NUMBER OF SEQ ID NOS: 10
20 <170> SOFTWARE: PatentIn version 3.3
22 <210> SEQ ID NO: 1
23 <211> LENGTH: 3031
24 <212> TYPE: DNA
25 <213> ORGANISM: Homo sapiens
27 <400> SEQUENCE: 1
28 cctcgtgccg aattcggcac gaggcccgcc ggcggtggcg cggcggagac ccggctggta    60
30 taacaagagg attgcctgat ccagccaaga tgcagagcac ttctaatcat ctgtggcttt   120
32 tatctgatat tttaggccaa ggagctactg caaatgtctt tcgtggaaga cataagaaaa   180
34 ctggtgattt atttgctatc aaagtatttta ataacataag cttccttcgt ccagtggatg   240
36 ttcaaatgag agaatttgaa gtgttgaaaa aactcaatca caaaaatatt gtcaaattat   300
38 ttgctattga agaggagaca acaacaagac ataaagtact tattatggaa ttttgtccat   360
40 gtgggagttt atacactgtt ttagaagaac cttctaatgc ctatggacta ccagaatctg   420
42 aattcttaat tgttttgcga gatgtggtgg gtggaatgaa tcatctacga gagaatggta   480
44 tagtgcaccg tgatatcaag ccaggaaata tcatgcgtgt tataggggaa gatggacagt   540
46 ctgtgtacaa actcacagat tttggtgcag ctagagaatt agaagatgat gagcagtttg   600
48 tttctctgta tggcacagaa gaatatttgc accctgatat gtatgagaga gcagtgctaa   660
50 gaaaagatca tcagaagaaa tatggagcaa cagttgatct ttggagcatt ggggtaacat   720
52 tttaccatgc agctactgga tcactgccat ttagaccctt tgaagggcct cgtaggaata   780
54 aagaagtgat gtataaaata attacaggaa agccttctgg tgcaatatct ggagtacaga   840
56 aagcagaaaa tggaccaatt gactggagtg gagacatgcc tgtttcttgc agtctttctc   900
58 ggggtcttca ggttctactt acccctgttc ttgcaaacat ccttgaagca gatcaggaaa   960
60 agtgttgggg ttttgaccag ttttttgcag aaactagtga tatacttcac cgaatggtaa  1020
62 ttcatgtttt ttcgctacaa caaatgacag ctcataagat ttatattcat agctataata  1080
64 ctgctactat atttcatgaa ctggtatata aacaaaccaa aattatttct tcaaatcaag  1140
66 aacttatcta cgaagggcga cgcttagtct tagaacctgg aaggctggca aacatttcc   1200
68 ctaaaactac tgaggaaaac cctatatttg tagtaagccg ggaacctctg aataccatag  1260
70 gattaatata tgaaaaaatt tccctcccta aagtacatcc acgttatgat ttagacgggg  1320
72 atgctagcat ggctaaggca ataacagggg ttgtgtgtta tgcctgcaga attgccagta  1380
74 ccttactgct ttatcaggaa ttaatgcgaa aggggatacg atggctgatt gaattaatta  1440
76 aagatgatta caatgaaact gttcacaaaa agacagaagt tgtgatcaca ttggatttct  1500
78 gtatcagaaa cattgaaaaa actgtgaaag tatatgaaaa gttgatgaag atcaacctgg  1560
80 aagcggcaga gttaggtgaa atttcagaca tacacaccaa attgttgaga ctttccagtt  1620
```

```
 82 ctcagggaac aatagaaacc agtcttcagg atatcgacag cagattatct ccaggtggat    1680
 84 cactggcaga cgcatgggca catcaagaag gcactcatcc gaaagacaga aatgtagaaa    1740
 86 aactacaagt cctgttaaat tgcatgacag agatttacta tcagttcaaa aaagacaaag    1800
 88 cagaacgtag attagcttat aatgaagaac aaatccacaa atttgataag caaaaactgt    1860
 90 attaccatgc cacaaaagct atgacgcact ttacagatga atgtgttaaa aagtatgagg    1920
 92 cattttgaa taagtcagaa gaatggataa gaaagatgct tcatcttagg aaacagttat    1980
 94 tatcgctgac taatcagtgt tttgatattg aagaagaagt atcaaaatat caagaatata    2040
 96 ctaatgagtt acaagaaact ctgcctcaga aaatgtttac agcttccagt ggaatcaaac    2100
 98 ataccatgac cccaatttat ccaagttcta acacattagt agaaatgact cttggtatga    2160
100 agaaattaaa ggaagagatg gaaggggtgg ttaaagaact tgctgaaaat aaccacattt    2220
102 tagaaaggtt tggctcttta accatggatg gtggccttcg caacgttgac tgtctttagc    2280
104 tttctaatag aagtttaaga aaagtttccg tttgcacaag aaaataacgc ttgggcatta    2340
106 aatgaatgcc tttatagata gtcacttgtt tctacaattc agtatttgat gtggtcgtgt    2400
108 aaatatgtac aatattgtaa atacataaaa aatatacaaa tttttggctg ctgtgaagat    2460
110 gtaattttat cttttaacat ttataattat atgaggaaat ttgacctcag tgatcacgag    2520
112 aagaaagcca tgaccgacca atatgttgac atactgatcc tctactctga gtggggctaa    2580
114 ataagttatt ttctctgacc gcctactgga aatattttta agtggaacca aaataggcat    2640
116 ccttacaaat caggaagact gacttgacac gtttgtaaat ggtagaacgg tggctactgt    2700
118 gagtggggag cagaaccgca ccactgttat actgggataa caattttttt gagaaggata    2760
120 aagtggcatt attttatttt acaaggtgcc cagatcccag ttatccttgt atccatgtaa    2820
122 tttcagatga attattaagc aaacatttta aagtgaattc attattaaaa actattcatt    2880
124 ttttttccttt ggccataaat gtgtaattgt cattaaaatt ctaaggtcat ttcaactgtt    2940
126 ttaagctgta tatttctttta attctgctta ctatttcatg gaaaaaaata aatttctcaa    3000
128 ttttaatgta aagaaaaaaa aaaaaaaaaa a    3031
131 <210> SEQ ID NO: 2
132 <211> LENGTH: 729
133 <212> TYPE: PRT
134 <213> ORGANISM: Homo sapiens
136 <400> SEQUENCE: 2
138 Met Gln Ser Thr Ser Asn His Leu Trp Leu Leu Ser Asp Ile Leu Gly
139 1               5                   10                  15
142 Gln Gly Ala Thr Ala Asn Val Phe Arg Gly Arg His Lys Lys Thr Gly
143             20                  25                  30
146 Asp Leu Phe Ala Ile Lys Val Phe Asn Asn Ile Ser Phe Leu Arg Pro
147         35                  40                  45
150 Val Asp Val Gln Met Arg Glu Phe Glu Val Leu Lys Lys Leu Asn His
151     50                  55                  60
154 Lys Asn Ile Val Lys Leu Phe Ala Ile Glu Glu Glu Thr Thr Thr Arg
155 65                  70                  75                  80
158 His Lys Val Leu Ile Met Glu Phe Cys Pro Cys Gly Ser Leu Tyr Thr
159             85                  90                  95
162 Val Leu Glu Glu Pro Ser Asn Ala Tyr Gly Leu Pro Glu Ser Glu Phe
163             100                 105                 110
166 Leu Ile Val Leu Arg Asp Val Val Gly Gly Met Asn His Leu Arg Glu
167         115                 120                 125
170 Asn Gly Ile Val His Arg Asp Ile Lys Pro Gly Asn Ile Met Arg Val
171         130                 135                 140
174 Ile Gly Glu Asp Gly Gln Ser Val Tyr Lys Leu Thr Asp Phe Gly Ala
175 145                 150                 155                 160
```

RAW SEQUENCE LISTING   DATE: 03/13/2007
PATENT APPLICATION: US/10/574,306   TIME: 08:29:13

Input Set : A:\50458.002001.txt
Output Set: N:\CRF4\03132007\J574306.raw

```
178 Ala Arg Glu Leu Glu Asp Asp Glu Gln Phe Val Ser Leu Tyr Gly Thr
179             165                 170                 175
182 Glu Glu Tyr Leu His Pro Asp Met Tyr Glu Arg Ala Val Leu Arg Lys
183             180                 185                 190
186 Asp His Gln Lys Lys Tyr Gly Ala Thr Val Asp Leu Trp Ser Ile Gly
187         195                 200                 205
190 Val Thr Phe Tyr His Ala Ala Thr Gly Ser Leu Pro Phe Arg Pro Phe
191     210                 215                 220
194 Glu Gly Pro Arg Arg Asn Lys Glu Val Met Tyr Lys Ile Ile Thr Gly
195 225             230                 235                 240
198 Lys Pro Ser Gly Ala Ile Ser Gly Val Gln Lys Ala Glu Asn Gly Pro
199             245                 250                 255
202 Ile Asp Trp Ser Gly Asp Met Pro Val Ser Cys Ser Leu Ser Arg Gly
203         260                 265                 270
206 Leu Gln Val Leu Leu Thr Pro Val Leu Ala Asn Ile Leu Glu Ala Asp
207         275                 280                 285
210 Gln Glu Lys Cys Trp Gly Phe Asp Gln Phe Phe Ala Glu Thr Ser Asp
211     290                 295                 300
214 Ile Leu His Arg Met Val Ile His Val Phe Ser Leu Gln Gln Met Thr
215 305             310                 315                 320
218 Ala His Lys Ile Tyr Ile His Ser Tyr Asn Thr Ala Thr Ile Phe His
219             325                 330                 335
222 Glu Leu Val Tyr Lys Gln Thr Lys Ile Ile Ser Ser Asn Gln Glu Leu
223         340                 345                 350
226 Ile Tyr Glu Gly Arg Arg Leu Val Leu Glu Pro Gly Arg Leu Ala Gln
227         355                 360                 365
230 His Phe Pro Lys Thr Thr Glu Glu Asn Pro Ile Phe Val Val Ser Arg
231     370                 375                 380
234 Glu Pro Leu Asn Thr Ile Gly Leu Ile Tyr Glu Lys Ile Ser Leu Pro
235 385             390                 395                 400
238 Lys Val His Pro Arg Tyr Asp Leu Asp Gly Asp Ala Ser Met Ala Lys
239             405                 410                 415
242 Ala Ile Thr Gly Val Val Cys Tyr Ala Cys Arg Ile Ala Ser Thr Leu
243         420                 425                 430
246 Leu Leu Tyr Gln Glu Leu Met Arg Lys Gly Ile Arg Trp Leu Ile Glu
247         435                 440                 445
250 Leu Ile Lys Asp Asp Tyr Asn Glu Thr Val His Lys Lys Thr Glu Val
251     450                 455                 460
254 Val Ile Thr Leu Asp Phe Cys Ile Arg Asn Ile Glu Lys Thr Val Lys
255 465             470                 475                 480
258 Val Tyr Glu Lys Leu Met Lys Ile Asn Leu Glu Ala Ala Glu Leu Gly
259             485                 490                 495
262 Glu Ile Ser Asp Ile His Thr Lys Leu Leu Arg Leu Ser Ser Ser Gln
263         500                 505                 510
266 Gly Thr Ile Glu Thr Ser Leu Gln Asp Ile Asp Ser Arg Leu Ser Pro
267         515                 520                 525
270 Gly Gly Ser Leu Ala Asp Ala Trp Ala His Gln Glu Gly Thr His Pro
271     530                 535                 540
274 Lys Asp Arg Asn Val Glu Lys Leu Gln Val Leu Leu Asn Cys Met Thr
```

RAW SEQUENCE LISTING   DATE: 03/13/2007
PATENT APPLICATION: US/10/574,306   TIME: 08:29:13

Input Set : A:\50458.002001.txt
Output Set: N:\CRF4\03132007\J574306.raw

```
275 545                      550                      555                      560
278 Glu Ile Tyr Tyr Gln Phe Lys Lys Asp Lys Ala Glu Arg Arg Leu Ala
279                 565                      570                      575
282 Tyr Asn Glu Glu Gln Ile His Lys Phe Asp Lys Gln Lys Leu Tyr Tyr
283             580                      585                      590
286 His Ala Thr Lys Ala Met Thr His Phe Thr Asp Glu Cys Val Lys Lys
287         595                  .    600                      605
290 Tyr Glu Ala Phe Leu Asn Lys Ser Glu Glu Trp Ile Arg Lys Met Leu
291     610 .                    615                      620
294 His Leu Arg Lys Gln Leu Leu Ser Leu Thr Asn Gln Cys Phe Asp Ile
295 625                      630                      635                      640
298 Glu Glu Glu Val Ser Lys Tyr Gln Glu Tyr Thr Asn Glu Leu Gln Glu
299             645                      650                      655
302 Thr Leu Pro Gln Lys Met Phe Thr Ala Ser Ser Gly Ile Lys His Thr
303             660                      665                      670
306 Met Thr Pro Ile Tyr Pro Ser Ser Asn Thr Leu Val Glu Met Thr Leu
307         675                      680                      685
310 Gly Met Lys Lys Leu Lys Glu Glu Met Glu Gly Val Val Lys Glu Leu
311     690                      695                      700
314 Ala Glu Asn Asn His Ile Leu Glu Arg Phe Gly Ser Leu Thr Met Asp
315 705                      710                      715                      720
318 Gly Gly Leu Arg Asn Val Asp Cys Leu
319                 725
322 <210> SEQ ID NO: 3
323 <211> LENGTH: 19
324 <212> TYPE: RNA
325 <213> ORGANISM: artificial
327 <220> FEATURE:
328 <223> OTHER INFORMATION: oligonucleotide siTBK-1 sense
330 <400> SEQUENCE: 3
331 ggagacaaca acaagacau                                              19
334 <210> SEQ ID NO: 4
335 <211> LENGTH: 20
336 <212> TYPE: RNA
337 <213> ORGANISM: artificial
339 <220> FEATURE:
340 <223> OTHER INFORMATION: oligonucleotide siTBK-1 antisense
342 <400> SEQUENCE: 4
343 augucuuguu guugucuccc                                            20
346 <210> SEQ ID NO: 5
347 <211> LENGTH: 23
348 <212> TYPE: DNA
349 <213> ORGANISM: artificial
351 <220> FEATURE:
352 <223> OTHER INFORMATION: oligonucleotide TBK-1 sense
354 <400> SEQUENCE: 5
355 ttgaagagga gacaacaaca aga                                        23
358 <210> SEQ ID NO: 6
359 <211> LENGTH: 19
```

RAW SEQUENCE LISTING   DATE: 03/13/2007
PATENT APPLICATION: US/10/574,306   TIME: 08:29:13

        Input Set : A:\50458.002001.txt
        Output Set: N:\CRF4\03132007\J574306.raw

360 <212> TYPE: DNA
361 <213> ORGANISM: artificial
363 <220> FEATURE:
364 <223> OTHER INFORMATION: oligonucleotide TBK-1 antisense
366 <400> SEQUENCE: 6
367 cattccaccc accacatct   19
370 <210> SEQ ID NO: 7
371 <211> LENGTH: 20
372 <212> TYPE: DNA
373 <213> ORGANISM: artificial
375 <220> FEATURE:
376 <223> OTHER INFORMATION: oligonucleotide VEGF sense
378 <400> SEQUENCE: 7
379 cttgccttgc tgctctacct   20
382 <210> SEQ ID NO: 8
383 <211> LENGTH: 20
384 <212> TYPE: DNA
385 <213> ORGANISM: artificial
387 <220> FEATURE:
388 <223> OTHER INFORMATION: oligonucleotide VEGF antisense
390 <400> SEQUENCE: 8
391 gattctgccc tcctccttct   20
394 <210> SEQ ID NO: 9
395 <211> LENGTH: 20
396 <212> TYPE: DNA
397 <213> ORGANISM: artificial
399 <220> FEATURE:
400 <223> OTHER INFORMATION: oligonucleotide Rantes sense
402 <400> SEQUENCE: 9
403 cgctgtcatc ctcattgcta   20
406 <210> SEQ ID NO: 10
407 <211> LENGTH: 20
408 <212> TYPE: DNA
409 <213> ORGANISM: artificial
411 <220> FEATURE:
412 <223> OTHER INFORMATION: oligonucleotide Rantes antisense
414 <400> SEQUENCE: 10
415 gcacttgcca ctggtgtaga   20

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 03/13/2007
PATENT APPLICATION: US/10/574,306 TIME: 08:29:14

  Input Set : A:\50458.002001.txt
  Output Set: N:\CRF4\03132007\J574306.raw

Invalid <213> Response:
Use of "Artificial" only as "<213> Organism" response is incomplete,
per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:3,4,5,6,7,8,9,10

VERIFICATION SUMMARY DATE: 03/13/2007
PATENT APPLICATION: US/10/574,306 TIME: 08:29:14

Input Set : A:\50458.002001.txt
Output Set: N:\CRF4\03132007\J574306.raw